Alkermes to Participate in Two Upcoming Investor Conferences
Alkermes (Nasdaq: ALKS) said management will participate in two investor conferences in November 2025: the Stifel 2025 Healthcare Conference on Nov. 13, 2025 at 2:40 p.m. ET and the Jefferies Global Healthcare Conference in London on Nov. 19, 2025 at 11:30 a.m. ET.
Both events will be webcast live and the webcasts will be available under the Investors tab at www.alkermes.com and archived for 14 days.
Alkermes (Nasdaq: ALKS) ha dichiarato che la direzione parteciperà a due conferenze per investitori nel novembre 2025: la Stifel 2025 Healthcare Conference il 13 novembre 2025 alle 14:40 ET e la Jefferies Global Healthcare Conference a Londra il 19 novembre 2025 alle 11:30 ET. Entrambi gli eventi saranno trasmessi in diretta e le webcast saranno disponibili nella scheda Investitori su www.alkermes.com e archiviate per 14 giorni.
Alkermes (Nasdaq: ALKS) dijo que la dirección participará en dos conferencias para inversionistas en noviembre de 2025: la Conferencia de Salud 2025 de Stifel el 13 de noviembre de 2025 a las 2:40 p.m. hora del Este y la Conferencia Global de Salud de Jefferies en Londres el 19 de noviembre de 2025 a las 11:30 a.m. hora del Este.
Ambos eventos se transmitirán en vivo y las transmisiones estarán disponibles bajo la pestaña de Inversionistas en www.alkermes.com y quedarán archivadas durante 14 días.
Alkermes (나스닥: ALKS)는 2025년 11월 두 차례의 투자자 회의에 경영진이 참여할 것이라고 밝혔습니다: Stifel 2025 Healthcare Conference가 2025년 11월 13일 동부표준시 14:40에, Jefferies Global Healthcare Conference in London가 2025년 11월 19일 동부표준시 11:30에 열립니다. 두 행사 모두 생중계되며, 생방송은 www.alkermes.com의 투자자 탭에서 확인 가능하고 14일간 보관됩니다.
Alkermes (Nasdaq: ALKS) a déclaré que la direction participera à deux conférences pour investisseurs en novembre 2025 : la Stifel 2025 Healthcare Conference le 13 novembre 2025 à 14 h 40, heure de l'Est et la Jefferies Global Healthcare Conference à Londres le 19 novembre 2025 à 11 h 30, heure de l'Est.
Les deux événements seront diffusés en direct et les webcasts seront disponibles dans l’onglet Investisseurs sur www.alkermes.com et archivés pendant 14 jours.
Alkermes (Nasdaq: ALKS) sagte, dass das Management an zwei Investorenkonferenzen im November 2025 teilnehmen wird: die Stifel 2025 Healthcare Conference am 13. November 2025 um 14:40 Uhr EST und die Jefferies Global Healthcare Conference in London am 19. November 2025 um 11:30 Uhr EST. Beide Veranstaltungen werden live gestreamt, und die Webcasts sind unter dem Reiter "Investoren" auf www.alkermes.com verfügbar und für 14 Tage archiviert.
Alkermes (ناسداك: ALKS) قالت أن الإدارة ستشارك في مؤتمرين للمستثمرين في نوفمبر 2025: مؤتمر ستيفل للرعاية الصحية 2025 في 13 نوفمبر 2025 الساعة 2:40 مساءً بتوقيت شرق الولايات المتحدة ومؤتمر Jefferies العالمي للرعاية الصحية في لندن في 19 نوفمبر 2025 الساعة 11:30 صباحاً بتوقيت شرق الولايات المتحدة. سيُبَث الحدثان مباشرةً وستكون البثوث متاحة ضمن علامة التبويب المستثمرين على www.alkermes.com ومؤرشَفة لمدة 14 يوماً.
- None.
- None.
Stifel 2025 Healthcare Conference
Date/Time: Thursday, Nov. 13, 2025 at 2:40 p.m. ET (7:40 p.m. GMT)
Jefferies Global Healthcare Conference in
Date/Time: Wednesday, Nov. 19, 2025 at 11:30 a.m. ET (4:30 p.m. GMT)
The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
About Alkermes plc
Alkermes plc (Nasdaq: ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in
Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402
View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-participate-in-two-upcoming-investor-conferences-302607396.html
SOURCE Alkermes plc